{"result": "(\"entity\"<|>ACTH<|>ORGANIZATION<|>ACTH (Adrenocorticotropic hormone) is a hormone produced by the pituitary gland that stimulates the adrenal glands to release cortisol, playing a key role in Cushing's syndrome.)\n##\n(\"entity\"<|>CORTISOL<|>ORGANIZATION<|>Cortisol is a steroid hormone produced by the adrenal glands, often elevated in patients with Cushing's syndrome.)\n##\n(\"entity\"<|>11-β-HYDROXYLASE<|>ORGANIZATION<|>11-β-hydroxylase is an enzyme involved in cortisol synthesis, which can be inhibited by medications like etomidate.)\n##\n(\"entity\"<|>17,20-HYDROXYLASE<|>ORGANIZATION<|>17,20-hydroxylase is an enzyme that plays a role in steroid hormone synthesis, which can also be affected by certain treatments for Cushing's syndrome.)\n##\n(\"entity\"<|>HYPERADRENOCORTICISM<|>EVENT<|>Hyperadrenocorticism is a condition characterized by excessive production of adrenal hormones, often synonymous with Cushing's syndrome.)\n##\n(\"relationship\"<|>ACTH<|>CORTISOL<|>ACTH stimulates the adrenal glands to produce cortisol, which is often elevated in Cushing's syndrome<|>8)\n##\n(\"relationship\"<|>CORTISOL<|>CUSHING'S SYNDROME<|>Cushing's syndrome is characterized by elevated levels of cortisol in the body<|>9)\n##\n(\"relationship\"<|>ETOMIDATE<|>11-β-HYDROXYLASE<|>Etomidate inhibits the enzyme 11-β-hydroxylase, affecting cortisol synthesis<|>7)\n##\n(\"relationship\"<|>ETOMIDATE<|>17,20-HYDROXYLASE<|>Etomidate also inhibits the enzyme 17,20-hydroxylase, impacting steroid hormone production<|>7)\n##\n(\"relationship\"<|>TRILOSTANE<|>HYPERADRENOCORTICISM<|>Trilostane is used to treat hyperadrenocorticism by blocking steroid hormone synthesis<|>8)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: los glucocorticoides exógenos son capaces de inhibir la se-\n\n\n\n262                                                                                                                                                                                                                                                                    263\n---\n                                                                                                                                                                                                                                SUPRARRENALES                                           5\n\n\n\n         creción de ACTH. Un sello distintivo bioquímico clave de la enfermedad de Cushing es una                                                 El etomidato es un            anestésico no         opiáceo      (derivado imidazólico) de               administración intra-\n         resistencia relativa de la secreción de ACTH a la inhibición por retroalimentación normal                                                venosa que, a dosis no hipnóticas, suprime la síntesis suprarrenal de cortisol, inhibiendo\n         de los glucocorticoides.                                                                                                                 de manera reversible las enzimas 11-β-hidroxilasa y 17,20-hiroxilasa. Su inicio de acción es\n         Referencias:                                                                                                                             muy rápido, en pocas horas, y su uso se limita a situaciones clínicas en las que sea urgente\n         •  Arlt W. Trastornos de la corteza suprarrenal. En: Kasper DL, Hauser SL, Jameson JL, Fauci AS, Longo DL, Loscazo J, eds. Harrison      descender el nivel de cortisol.\n            Principios de Medicina Interna. 19.ª edición en español. México DF: Mc Graw Hill; 2016. p. 2309-29.                                   El trilostano bloquea la síntesis de hormonas esteroideas suprarrenales (indicado en perros\n         •  Estrada J, Abad A, Aller J. Síndrome de Cushing. Manual de Endocrinología y Nutrición. Disponible en: https://manual.seen.es\n            (última modificación: 25 de noviembre de 2015).                                                                                       para el tratamiento           del hiperadrenocorticismo por enfermedad                         o síndrome de Cushing).\n         •  Nieman LK. Epidemiology and clinical manifestations of Cushing’s syndrome. UpToDate. Waltham, MA: UpToDate Inc. https://www.\n            uptodate.com. Literature review current through: Apr. 2019.                                                                           La   mifepristona es un antagonista de progesterona que, en dosis elevadas, bloquea tam-\n         •  Nieman LK. Establishing the diagnosis of Cushing’s syndrome. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com.           bién el receptor de glucocorticoides.\n            Literature review current through: Apr. 2019.\n         •  Nieman LK. Overview of the treatment of Cushing’s syndrome. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com.            Referencias:\n            Literature review current through: Apr. 2019.                                                                                         • Arlt W. Trastornos de la corteza suprarrenal. En: Kasper DL, Hauser SL, Jameson JL, Fauci AS, Longo DL, Loscazo J, eds. Harrison\n         •  Nieman LK, Biller BMK, Findiling JW, Murad MH, Newel-Price J, Savage MO, et al. Treatment of Cushing’s syndrome:                        Principios de Medicina Interna. 19.ª edición en español. México DF: Mc Graw Hill; 2016. p. 2309-29.\n            an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015;100:2807-31.                                          • Estrada J, Abad A, Aller J. Síndrome de Cushing. Manual de Endocrinología y Nutrición. Disponible en: https://manual.seen.es\n         •  Nieman LK, Biller BMK, Findiling JW, Newel-Price J, Savage MO, Steward PM, et al. The diagnosis of Cushing’s syndrome:                  (última modificación: 25 de noviembre de 2015).\n            an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008;93:1526-40.                                           • Nieman LK. Epidemiology and clinical manifestations of Cushing’s syndrome. UpToDate. Waltham, MA: UpToDate Inc. https://www.\n         •  Steward PM, Newell-Price JDC. The adrenal cortex. En: Melmed S, Polonsky KS, Larsen PR, Kronenberg HM, eds. Williams Textbook           uptodate.com. Literature review current through: Apr. 2019.\n            of Endocrinology. 13.ª ed. Philadelphia, Elsevier; 2016. p. 490-555.                                                                  • Nieman LK. Establishing the diagnosis of Cushing’s syndrome. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com.\n                                                                                                                                                    Literature review current through: Apr. 2019.\n                                                                                                                                                  • Nieman LK. Overview of the treatment of Cushing’s syndrome. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com.\n                                                                                                                                                    Literature review current through: Apr. 2019.\n     10  En    ocasiones hay           que utilizar       tratamiento médico               para el control de la enfermedad                       • Nieman LK, Biller BMK, Findiling JW, Murad MH, Newel-Price\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>CUSHING'S SYNDROME<|>EVENT<|>Cushing's syndrome is a hormonal disorder caused by prolonged exposure to high levels of cortisol, often leading to various health complications.)\n##\n(\"entity\"<|>ETOMIDATE<|>ORGANIZATION<|>Etomidate is a non-opioid anesthetic used for rapid induction in anesthesia, which suppresses adrenal cortisol synthesis.)\n##\n(\"entity\"<|>TRILOSTANE<|>ORGANIZATION<|>Trilostane is a medication that blocks the synthesis of adrenal steroid hormones, indicated for treating hyperadrenocorticism in dogs.)\n##\n(\"entity\"<|>MIFEPRISTONE<|>ORGANIZATION<|>Mifepristone is a progesterone antagonist that, at high doses, also blocks glucocorticoid receptors.)\n##\n(\"entity\"<|>UPTODATE INC.<|>ORGANIZATION<|>UpToDate Inc. is a clinical decision support resource providing evidence-based information for healthcare professionals.)\n##\n(\"entity\"<|>HARRISON'S PRINCIPLES OF INTERNAL MEDICINE<|>ORGANIZATION<|>Harrison's Principles of Internal Medicine is a comprehensive medical textbook covering various aspects of internal medicine.)\n##\n(\"entity\"<|>MANUAL DE ENDOCRINOLOGÍA Y NUTRICIÓN<|>ORGANIZATION<|>Manual de Endocrinología y Nutrición is a reference manual focused on endocrinology and nutrition.)\n##\n(\"entity\"<|>KASPER DL<|>PERSON<|>Kasper DL is one of the editors of Harrison's Principles of Internal Medicine, contributing to the field of internal medicine.)\n##\n(\"entity\"<|>NIEMAN LK<|>PERSON<|>Nieman LK is a medical professional known for contributions to the understanding and treatment of Cushing's syndrome.)\n##\n(\"relationship\"<|>ETOMIDATE<|>CUSHING'S SYNDROME<|>Etomidate is used in clinical situations to manage conditions like Cushing's syndrome by suppressing cortisol synthesis<|>7)\n##\n(\"relationship\"<|>TRILOSTANE<|>CUSHING'S SYNDROME<|>Trilostane is indicated for the treatment of hyperadrenocorticism, a condition related to Cushing's syndrome<|>8)\n##\n(\"relationship\"<|>MIFEPRISTONE<|>CUSHING'S SYNDROME<|>Mifepristone is used in high doses to block glucocorticoid receptors in patients with Cushing's syndrome<|>7)\n##\n(\"relationship\"<|>NIEMAN LK<|>CUSHING'S SYNDROME<|>Nieman LK has authored guidelines and literature on the diagnosis and treatment of Cushing's syndrome<|>9)\n##\n(\"relationship\"<|>KASPER DL<|>HARRISON'S PRINCIPLES OF INTERNAL MEDICINE<|>Kasper DL is an editor of Harrison's Principles of Internal Medicine, which includes information on Cushing's syndrome<|>6)\n##\n(\"relationship\"<|>UPTODATE INC.<|>CUSHING'S SYNDROME<|>UpToDate Inc. provides clinical guidelines and information on the management of Cushing's syndrome<|>8)\n##\n(\"relationship\"<|>MANUAL DE ENDOCRINOLOGÍA Y NUTRICIÓN<|>CUSHING'S SYNDROME<|>The Manual de Endocrinología y Nutrición includes references and guidelines for managing Cushing's syndrome<|>6)\n<|COMPLETE|>"}]}